Current trends in diagnostic biomarkers of acute coronary syndrome

Annals of the Academy of Medicine Singapore

Volumn 39, Issue 3, 2010, Pages 210-215

  Moe, Kyaw Thu ^a   Wong, Philip ^b  

^a DEPARTMENT OF CARDIOLOGY   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Cardiac troponin; Creatine kinase; NSTEMI

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATINE KINASE; FATTY ACID BINDING PROTEIN; INTERLEUKIN 6; MYELOPEROXIDASE; MYOGLOBIN; OXIDIZED LOW DENSITY LIPOPROTEIN; SECRETORY PHOSPHOLIPASE A2; TROPONIN; TROPONIN I; TROPONIN T;

ACUTE CORONARY SYNDROME; DISEASE COURSE; EARLY DIAGNOSIS; HUMAN; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PATIENT CARE; POINT OF CARE TESTING; REVIEW; RISK ASSESSMENT; TREND STUDY; UNSTABLE ANGINA PECTORIS;

EID: 77950910235     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem 2007;53:552-74.
2. Wiviott SD, Braunwald E. Unstable angina and non-ST-segment elevation myocardial infarction: part I. Initial evaluation and management, and hospital care. Am Fam Physician 2004;70:525-32.
3. Boden WE, McKay RG. Optimal treatment of acute coronary syndromes- an evolving strategy. N Engl J Med 2001;344:1939-42.
4. Yarlagadda RK, Boden WE. Cardioprotective effects of an early invasive strategy for non-ST-segment elevation acute coronary syndromes: are we all becoming "interventional" cardiologists? J Am Coll Cardiol 2002;40:1915-8.
5. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-504.
6. Panteghini M. Acute coronary syndrome: biochemical strategies in the troponin era. Chest 2002;122:1428-35.
7. Canto JG, Shlipak MG, Rogers WJ, Malmgren JA, Frederick PD, Lambrew CT, et al. Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain. JAMA 2000;283:3223-9.
8. Storrow AB, Gibler WB. Chest pain centers: diagnosis of acute coronary syndromes. Ann Emerg Med 2000;35:449-61.
9. Dadkhah S, Sharain K, Sharain R, Kiabayan H, Foschi A, Zonia C, et al. The value of bedside cardiac multibiomarker assay in rapid and accurate diagnosis of acute coronary syndromes. Crit Pathw Cardiol 2007;6:76-84.
10. Rusnak RA, Stair TO, Hansen K, Fastow JS. Litigation against the emergency physician: common features in cases of missed myocardial infarction. Ann Emerg Med 1989;18:1029-34.
11. Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009;361:868-77.
12. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009;361:858-67.
13. Kavsak PA, Wang X, Ko DT, MacRae AR, Jaffe AS. Short- and long-term risk stratification using a next-generation, high-sensitivity research cardiac troponin I (hs-cTnI) assay in an emergency department chest pain population. Clin Chem 2009;55:1809-15.
14. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69.
15. Boden WE, Shah PK, Gupta V, Ohman EM. Contemporary approach to the diagnosis and management of non-ST-segment elevation acute coronary syndromes. Prog Cardiovasc Dis 2008;50:311-51.
16. Evaluation of a bedside whole-blood rapid troponin T assay in the emergency department. Rapid Evaluation by Assay of Cardiac Troponin T (REACTT) Investigators Study Group. Acad Emerg Med 1997;4: 1018-24.
17. Jaffe AS, Ravkilde J, Roberts R, Naslund U, Apple FS, Galvani M, et al. It's time for a change to a troponin standard. Circulation 2000;102: 1216-20.
18. Bonaca MP, Morrow DA. Defining a role for novel biomarkers in acute coronary syndromes. Clin Chem 2008;54:1424-31.
19. Bodor GS, Survant L, Voss EM, Smith S, Porterfield D, Apple FS. Cardiac troponin T composition in normal and regenerating human skeletal muscle. Clin Chem 1997;43:476-84.
20. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994;90:583-612.
21. Loria V, Leo M, Biasillo G, Dato I, Biasucci LM. Biomarkers in acute coronary syndrome. Biomark Insights 2008;3:453-68.
22. Gibler WB, Lewis LM, Erb RE, Makens PK, Kaplan BC, Vaughn RH, et al. Early detection of acute myocardial infarction in patients presenting with chest pain and nondiagnostic ECGs: serial CK-MB sampling in the emergency department. Ann Emerg Med 1990;19:1359-66.
23. Chia S, Senatore F, Raffel OC, Lee H, Wackers FJ, Jang IK. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2008;1:415-23.
24. Tzivoni D, Koukoui D, Guetta V, Novack L, Cowing G, CASTEMI study Investigators. Comparison of Troponin T to creatine kinase and to radionuclide cardiac imaging infarct size in patients with ST-elevation myocardial infarction undergoing primary angioplasty. Am J Cardiol 2008;101:753-7.
25. Apple FS, Murakami M, Panteghini M, Christenson RH, Dati F, Mair J, et al. International survey on the use of cardiac markers. Clin Chem 2001;47:587-8.
26. Selker HP, Zalenski RJ, Antman EM, Aufderheide TP, Bernard SA, Bonow RO, et al. An evaluation of technologies for identifying acute cardiac ischemia in the emergency department: executive summary of a National Heart Attack Alert Program Working Group Report. Ann Emerg Med 1997;29:1-12.
27. de Winter RJ, Lijmer JG, Koster RW, Hoek FJ, Sanders GT. Diagnostic accuracy of myoglobin concentration for the early diagnosis of acute myocardial infarction. Ann Emerg Med 2000;35:113-20.
28. Ohman EM, Casey C, Bengtson JR, Pryor D, Tormey W, Horgan JH. Early detection of acute myocardial infarction: additional diagnostic information from serum concentrations of myoglobin in patients without ST elevation. Br Heart J 1990;63:335-8.
29. Brogan GX Jr, Friedman S, McCuskey C, Cooling DS, Berrutti L, Thode HC Jr, et al. Evaluation of a new rapid quantitative immunoassay for serum myoglobin versus CK-MB for ruling out acute myocardial infarction in the emergency department. Ann Emerg Med 1994;24:665-71.
30. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362:316-22.
31. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21.
32. Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993;88:82-91.
33. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002;40:437-45.
34. Clerico A, Iervasi G, Mariani G. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans. Horm Metab Res 1999;31:487-98.
35. Pietila K, Hermens WT, Harmoinen A, Baardman T, Pasternack A, Topol EJ, et al. Comparison of peak serum C-reactive protein and hydroxybutyrate dehydrogenase levels in patients with acute myocardial infarction treated with alteplase and streptokinase. Am J Cardiol 1997;80:1075-7.
36. Ueda S, Ikeda U, Yamamoto K, Takahashi M, Nishinaga M, Nago N, et al. C-reactive protein as a predictor of cardiac rupture after acute myocardial infarction. Am Heart J 1996;131:857-60.
37. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.
38. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-42.
39. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;331:417-24.
40. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA 2001;286:2107-13.
41. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
42. Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes: part I: introduction and cytokines. Circulation 2006;113:e72-5.
43. Deo R, Khera A, McGuire DK, Murphy SA, Meo Neto Jde P, Morrow DA, et al. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol 2004;44:1812-8.
44. de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM, et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003;107:690-5.
45. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002;106:24-30.
46. Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes: part III: biomarkers of oxidative stress and angiogenic growth factors. Circulation 2006;113:e289-92.
47. Kleine AH, Glatz JF, Van Nieuwenhoven FA, Van der Vusse GJ. Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man. Mol Cell Biochem 1992;116:155-62.
48. Apple FS, Wu AH, Mair J, Ravkilde J, Panteghini M, Tate J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005;51:810-24.
49. Bhagavan NV, Lai EM, Rios PA, Yang J, Ortega-Lopez AM, Shinoda H, et al. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem 2003;49:581-5.
50. Hamm CW. Cardiac biomarkers for rapid evaluation of chest pain. Circulation 2001;104:1454-6.
51. Zimmerman J, Fromm R, Meyer D, Boudreaux A, Wun CC, Smalling R, et al. Diagnostic marker cooperative study for the diagnosis of myocardial infarction. Circulation 1999;99:1671-7.
52. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002;40:1366-74.
53. Christenson RH, Azzazy HM. Cardiac point of care testing: a focused review of current National Academy of Clinical Biochemistry guidelines and measurement platforms. Clin Biochem 2009;42:150-7.
54. Floriano PN, Christodoulides N, Miller CS, Ebersole JL, Spertus J, Rose BG, et al. Use of saliva-based nano-biochip tests for acute myocardial infarction at the point of care: a feasibility study. Clin Chem 2009;55: 1530-8.
55. Ng SY, Reboud J, Wang KY, Tang KC, Zhang L, Wong P, et al. Label-free impedance detection of low levels of circulating endothelial progenitor cells for point-of-care diagnosis. Biosens Bioelectron 2010;25:1095-101.
56. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007;13:1359-62.
57. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002;105:1760-3.
58. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006;355:2631-9.